Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Status:
Completed
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to evaluate the long-term safety and tolerability of
olokizumab (OKZ) 64 mg administered subcutaneously (SC) once every 2 weeks (q2w) or once
every 4 weeks (q4w) in subjects with moderately to severely active rheumatoid arthritis (RA)
who previously had completed 24 weeks of double-blind treatment in Study CREDO 1, 2 or 3
(core studies). The long-term efficacy, immunogenicity, the physical function and quality of
life of subjects received long-term treatment with OKZ were assessed as well.
Phase:
Phase 3
Details
Lead Sponsor:
R-Pharm R-Pharm International, LLC
Collaborators:
IQVIA Pvt. Ltd MENE Research OCT Clinical Trials Quintiles, Inc.